Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes ( LR ‐ MDS ) in the COMMANDS Study
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70171 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Rami S Komrokji und 9 weiteren Autor:innen. Beteiligte Einrichtung: Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Activin Receptors, Type II, Erythrocyte Transfusion, Immunoglobulin Fc Fragments, Mutation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
The COMMANDS trial established luspatercept as a first‐line treatment for anemia in transfusion‐dependent lower‐risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS trial. Of 350 evaluable patients, 238 (68.0%) had MDS with multiple lineage dysplasia and ring sideroblasts (RS) according to World Health Organization 2016 criteria, and 320 (91.4%) had somatic mutations in ≥ 1 gene (median, 2) with median variant allele frequencies (VAF) of 2%–59%. Mutation profiles were similar in the treatment groups. Luspatercept had superior responses versus epoetin alfa across multiple mutations (risk difference; RD, [95% confidence interval; CI] 0.25 [0.15–0.35]), including in SF3B1 ‐mutated (0.38 [0.25–0.50]) and SF3B1 wild‐type (0.09 [−0.11 to 0.30]). Luspatercept demonstrated superior responses in patients with VAF ≥ 10% (random effect, 0.36 [95% CI, 0.28–0.44]), and in those with 1 (63% vs. 40%; p = 0.040), 2 (70% vs. 27%; p < 0.001), and 3 (72% vs. 40%; p = 0.018) mutations, and across the low (75% vs. 38%), moderate low (61% vs. 38%), moderate high (44% vs. 21%), and high (36% vs. 24%) Molecular International Prognostic Scoring System risk groups (summary effect RD, 0.26 [95% CI, 0.14–0.37]). Across most mutations luspatercept responses were superior (random effect, 0.34 [95% CI, 0.24–0.44]) in patients with RS but were similar between treatments in RS‐negative patients. Luspatercept represents an effective treatment option in various mutational backgrounds in LR MDS. Trial Registration: ClinicalTrials.gov Identifier: NCT03682536.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Moffitt Cancer Center, Tampa, Florida, USA.
- Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.
- BMS Center for Innovation and Translational Research Europe (CITRE), Seville, Spain.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
ORCID-Profile: Rami S Komrokji, Guillermo Garcia-Manero, Valeria Santini, Rajasekhar N V S Suragani
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Komrokji, R. S., Hayati, S., Ugidos, M., Garcia-Manero, G., Della Porta, M. G., Zeidan, A. M., Santini, V., Platzbecker, U., Gandhi, A. K., & Suragani, R. N. V. S. (2026). Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes ( LR ‐ MDS ) in the COMMANDS Study. American Journal of Hematology. https://doi.org/10.1002/ajh.70171
Vancouver
Komrokji RS, Hayati S, Ugidos M, Garcia-Manero G, Della Porta MG, Zeidan AM, et al. Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes ( LR ‐ MDS ) in the COMMANDS Study. American Journal of Hematology. 2026. doi:10.1002/ajh.70171
BibTeX
@article{Komrokji2026,
author = {Komrokji, Rami S and Hayati, Sheida and Ugidos, Manuel and Garcia-Manero, Guillermo and Della Porta, Matteo Giovanni and Zeidan, Amer M and Santini, Valeria and Platzbecker, Uwe and Gandhi, Anita K and Suragani, Rajasekhar N V S},
title = {Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes ( LR ‐ MDS ) in the COMMANDS Study},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70171}
}
EUVIMED